MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Personalis Cash Conversion Cycle 2011-2026 | PSNL
Annual Cash Conversion Cycle Personalis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.5 | -6.34 | 20.6 | -6.42 | -26.4 | -31.6 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 | -31.6 | -10.3 |
Quarterly Cash Conversion Cycle Personalis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.16 | -9.89 | -6.41 | - | -13.4 | -10.9 | -10.4 | - | 4.47 | 1.37 | 7.26 | - | 1.99 | -6.3 | 6.27 | - | -11.5 | -15.7 | -18.8 | - | -23.1 | -21.4 | -24.2 | 16.6 | -40.5 | -48.4 | -37.7 | 30.9 | -48.6 | -23.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.9 | -48.6 | -12.1 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
45.9 | $ 39.6 | 0.66 % | $ 1.1 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
149 | $ 23.95 | 2.79 % | $ 258 M |  China |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
DexCom
DXCM
|
133 | $ 70.7 | 4.9 % | $ 27.3 B | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
299 | $ 6.01 | -2.91 % | $ 176 M | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
49.1 | $ 104.68 | -4.98 % | $ 12.8 B | USA |
 |
BioNano Genomics
BNGO
|
225 | $ 1.6 | 0.95 % | $ 2.03 M | USA |
 |
Illumina
ILMN
|
142 | $ 143.1 | 1.44 % | $ 22.8 B | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
IQVIA Holdings
IQV
|
78 | $ 239.3 | -1.3 % | $ 43.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M | China |
 |
Lantheus Holdings
LNTH
|
90.9 | $ 66.68 | -1.3 % | $ 4.61 B | USA |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
Medpace Holdings
MEDP
|
51.5 | $ 599.14 | 0.7 % | $ 18.5 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
76.4 | $ 20.14 | 17.57 % | $ 1.08 B | USA |
 |
Danaher Corporation
DHR
|
83.5 | $ 237.36 | -0.42 % | $ 174 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-1.24 K | $ 4.52 | -2.8 % | $ 2.43 M | USA |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
33 | $ 19.91 | 0.96 % | $ 489 M | USA |
 |
Natera
NTRA
|
81.5 | $ 233.53 | -0.34 % | $ 23 B | USA |
 |
DarioHealth Corp.
DRIO
|
207 | $ 12.0 | -1.32 % | $ 340 M |  Israel |
 |
Anixa Biosciences
ANIX
|
385 | $ 3.15 | -6.81 % | $ 100 K | USA |
 |
Pacific Biosciences of California
PACB
|
149 | $ 1.98 | 2.06 % | $ 502 M | USA |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
89 | $ 29.88 | 1.1 % | $ 20 B |  Niderland |
 |
Exact Sciences Corporation
EXAS
|
130 | $ 102.08 | -0.03 % | $ 18.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | $ 47.69 | -1.25 % | $ 10.6 B | Niderland |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 28.02 | 0.61 % | $ 847 M | USA |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Charles River Laboratories International
CRL
|
67.7 | $ 215.18 | -2.67 % | $ 11.1 B | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
Mettler-Toledo International
MTD
|
63.7 | $ 1 478.38 | -0.47 % | $ 31.4 B |  Schweiz |
 |
Thermo Fisher Scientific
TMO
|
69.8 | $ 610.0 | -1.44 % | $ 233 B | USA |
 |
Trinity Biotech plc
TRIB
|
136 | $ 0.73 | -1.14 % | $ 61.9 M |  Irlanda |
 |
Neogen Corporation
NEOG
|
150 | $ 9.09 | -5.56 % | $ 1.97 B | USA |
 |
Twist Bioscience Corporation
TWST
|
83.6 | $ 38.47 | 8.92 % | $ 2.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
38.6 | $ 173.92 | -0.3 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 8.15 | 49.32 % | $ 1.06 B | USA |